TTPH, Tetraphase Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TTPH, Tetraphase Pharmaceuticals

TTPH 2.200

-3.5%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	4/6/2016 9:07:37 AM
	of 80

Antimicrob Agents Chemother. 2016 Apr 4. pii: AAC.00436-16. [Epub ahead of print] In-vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Livermore DM1, Mushtaq S2, Warner M2, Woodford N2. 1Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, Public Health England, London Norwich Medical School, University of East Anglia, Norwich d.livermore@uea.ac.uk. 2Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, Public Health England, London. Eravacycline and comparators were tested against carbapenem- and tigecycline-resistant Enterobacteriaceae and Acinetobacter received at the United Kingdom's national reference laboratory Eravacycline MICs correlated closely with those of tigecycline but mostly were around two-fold lower; both molecule retained full activity against isolates with high-level tetracycline and minocycline resistance. MIC90s of eravacycline and tigecycline were raised ca. two-fold for carbapenem-resistant Enterobacteriaceae compared with carbapenem-susceptible controls, probably reflecting subsets of isolates with increased efflux.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next